Table 1.
Recent examples of liposome-based drug delivery systems for breast cancer therapy.
| Vesicular System | Drug/s/API/s | Pathway/Receptor/Targeting Moiety/ Overexpressed Factors/Mode of Action |
Progress | Reference |
|---|---|---|---|---|
| Ligand modified liposome | PTX | SMVTs receptors/biotin and glucose targeting complex | in vitro and in vivo |
[91] |
| Peptide Based liposome |
PTX | Folate receptors/Glutamic hexapeptide-folic acid-targeting complex | in vitro and in vivo |
[92] |
| Aptamer Based liposome |
DOX | Forkhead box M1 (FOXM1) aptamer |
in vitro and in vivo |
[93] |
| Peptide Based liposome |
PTX | Glutamic oligopeptide- RGD Peptide targeting moiety |
in vitro and in vivo |
[94] |
| Hydrophobic peptide-based liposome |
DOX | Hydrophobic penetrating peptide PFVYL1 targeting moiety | in vitro and in vivo |
[95] |
| HA modified Cationic liposome |
Honokiol (HNK) | CD44 receptors/HA-liposome-HNK targeting and therapeutic complex | in vitro and in vivo |
[96] |
| Drug-in-cyclodextrin in-liposome (DCL) | 17β-Estradiol | Membrane Isolated Steroid Signaling (MISS) pathway/Estrogen α receptors | in vitro and in vivo |
[97] |
| Aptamer based liposome | DOX | AS1411 targeting nucleotide/P-glycoprotein (P-gp) overexpression | in vitro and in vivo |
[98] |
| Drug based liposome | Tamoxifen and Raloxifene | Estrogen and progesterone receptors | in vitro and in vivo |
[99] |
| Drug based liposome | DOX | Protoporphyrin IX nucleus targeting complex | in vitro and in vivo |
[100] |
| API based liposome | N-alkylIsatin | SerpinB2 inhibitor/uPA/uPAR receptors and targeting ligand | in vitro and in vivo |
[101] |
| Drug and API based liposome | PTX, Cetuximab, and Piperine | EGFR inhibition pathways/EGFR receptors | in vitro | [102] |